CUAMC
CARM

China Universal Asset Management Company’s Carisma Therapeutics CARM Stock Holding History

China Universal Asset Management Company’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-93
Closed -$1K – 407
2022
Q3 		$1K Buy
+93
New +$1.27K ﹤0.01% 386

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BWA
Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

China Universal Asset Management Company's CARM Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 93 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in CARM in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 93 Carisma Therapeutics shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Carisma Therapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Carisma Therapeutics position peaked at $1K in Q3 2022.
  • 70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.